“Mesoblast will now focus on its original strategy to first gain pediatric approval for RYONCIL, followed by label extension in the larger adult population. ”
for SI to reconsider label extension again (plan A) instead of the adult trial (plan B), this spells out to me that the directions and guidance from the FDA minutes must be quite positive.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-66
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.010(0.72%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $1.169M | 834.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 57640 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 14386 | 12 |
View Market Depth
| Last trade - 10.56am 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |